The IGFBP5 Knockout KYSE-30 Polyclonal Cells product comprises a heterogeneous polyclonal population of KYSE-30 human esophageal squamous cell carcinoma cells that have been subjected to CRISPR/Cas9-mediated targeted disruption of the IGFBP5 gene. As a polyclonal knockout cell pool, this model provides a loss-of-function system for studying the tumor-suppressive roles of IGFBP5 without the clonal selection bias inherent in single-cell-derived lines. The cells are supplied as a ready-to-use population with confirmed gene editing, enabling researchers to bypass the time-consuming steps of genome engineering and immediately focus on downstream functional assays.
The parental KYSE-30 cell line is a well-differentiated invasive esophageal squamous cell carcinoma model established from a human primary tumor. This adherent epithelial line retains key features of esophageal cancer, including aggressive growth and invasive potential, making it a clinically relevant host for studying disease mechanisms. The line’s established use in esophageal squamous cell carcinoma research ensures compatibility with a wide range of existing protocols and comparative studies.
IGFBP5 encodes a secreted insulin-like growth factor binding protein that binds IGF-I and IGF-II with high affinity, functioning as a potent negative regulator of IGF signaling. By sequestering ligands away from the IGF1R receptor, IGFBP5 suppresses downstream PI3K-AKT and MAPK/ERK cascades, leading to reduced phosphorylation of AKT (Ser473) and ERK1/2 (Thr202/Tyr204), upregulation of the cyclin-dependent kinase inhibitor p21, and activation of caspase-3-dependent apoptosis. Additionally, IGFBP5 interacts with extracellular matrix components such as fibronectin and vitronectin through integrins and LRP1, exerting IGF-independent effects on cell adhesion and senescence. Transcription is positively regulated by tumor suppressors p53 and TGF-beta, placing IGFBP5 within broader growth-suppressive networks.
In the context of KYSE-30 cells, which exhibit constitutive IGF signaling activity, knockout of IGFBP5 is expected to remove a critical brake on ligand bioavailability, thereby potentiating IGF1R-mediated survival and proliferative pathways. This creates a relevant model to dissect how loss of IGFBP5 contributes to esophageal squamous cell carcinoma progression, metastasis, and resistance to apoptosis. The model also facilitates cross-disease comparisons with other IGFBP5-implicated malignancies, including breast and prostate cancers, as well as studies on fibrosis and metabolic syndrome where IGFBP5 modulates stromal?Cepithelial interactions.
This polyclonal knockout pool is suitable for a variety of research applications, including investigation of IGFBP5 tumor suppressor functions, analysis of IGF signaling pathway dynamics, and drug sensitivity profiling of agents targeting IGF1R or downstream kinases. Representative assays include western blotting for phosphorylated AKT and ERK1/2, RT-qPCR for p21 and Bcl-2 family member expression, MTT or colony formation proliferation assays, Annexin V apoptosis assays, caspase-3 activity measurements, and transwell migration/invasion assays. Co-immunoprecipitation can be employed to confirm abolished IGF1?CIGFBP5 interactions. For further information or technical support, please contact Ascent Research.
